Definition and origins
Ibogaine is a psychoactive indole alkaloid most commonly obtained from the root bark of Tabernanthe iboga, a plant native to Central and West Africa (notably Gabon and Cameroon).[1][2] It is described as hallucinogenic and “oneirogenic” (dream-inducing), and it has been used in spiritual and healing ceremonies within Bwiti traditions.[1][2]
In modern Western contexts, ibogaine is most frequently discussed in relation to addiction treatment, particularly opioid withdrawal interruption and reductions in craving, although the clinical evidence base is largely observational rather than based on large randomized controlled trials.[3][4]
Ibogaine is also referred to by various informal names; see Ibogaine Street Names, Slang & Nomenclature for terminology used in nonmedical settings.[2]
Pharmacology and metabolism (ibogaine vs. noribogaine)
Ibogaine has complex “polypharmacology,” meaning it interacts with multiple receptor and transporter systems implicated in reward, withdrawal, mood regulation, and learning.[1][3] Reported targets include serotonin, dopamine, opioid, sigma, NMDA, and nicotinic acetylcholine systems, among others described in reviews and summaries of the compound’s pharmacology.[1][3]
A major active metabolite is noribogaine (also called 12-hydroxyibogamine), which is often described as longer-lasting than the parent compound and is associated with serotonin reuptake inhibition in summaries of its mechanism.[1][3] Because both ibogaine and noribogaine may contribute to clinical effects and adverse events, discussions of “ibogaine treatment” commonly address the combined time course of the acute psychedelic experience and subsequent after-effects.[1][4]
Mechanistic explanations for ibogaine’s reported anti-addiction effects remain incomplete, and reviews generally treat its therapeutic rationale as multi-factorial rather than attributable to a single receptor action.[1][3]
Subjective effects, dosing, and duration
Ibogaine is notable for a long duration of action compared with many other psychedelics.[1] Descriptions of the experience often divide it into phases that may include an initial visionary (dream-like) phase, followed by introspective processing, and then residual after-effects (such as fatigue and sleep disruption).[1]
Nonmedical and clinic-reported dosing practices vary substantially by setting, preparation (e.g., alkaloid extract vs. ibogaine HCl), and individual factors, and commonly discussed regimens include test dosing followed by higher total dosing in a single session (sometimes described as a “flood dose”).[2] Because dosing is not standardized across countries or providers, the intensity and duration of effects can be unpredictable, which is one reason many medical sources emphasize screening and monitoring when ibogaine is used.[5][6]
For an overview of how ibogaine is typically administered in contemporary programs (including medical screening and aftercare), see What Is Ibogaine Treatment? | Evidence, Risks & Uses.[2][5]
History and Western medical context
Ibogaine’s traditional use in West and Central Africa predates its modern scientific and medical interest, and it is frequently discussed in connection with Bwiti spiritual practices in Gabon and neighboring regions.[1][2]
In Europe, purified ibogaine hydrochloride was marketed in France for a period in the mid-20th century (often referenced under the trade name “Lambarène”) before later restrictions and discontinuation.[1][2] Modern popularization of ibogaine as an anti-addiction intervention is widely associated with reports beginning in the 1960s describing reduced opioid withdrawal and craving after ibogaine use, which later motivated clinical observations and reviews.[2][3]
Academic reviews have periodically summarized ibogaine’s pharmacology, observational clinical reports, and safety concerns, while also noting that regulatory barriers and safety risks have limited conventional drug development of ibogaine itself compared with potential derivatives and analogs.[3][7]
Evidence and proposed therapeutic uses (addiction and beyond)
Ibogaine is most commonly sought for substance use disorders—especially opioid use disorder—based on reports that it can reduce acute withdrawal and decrease craving in some individuals after a single session.[3][4] A 2022 review in The Journal of Substance Abuse Treatment concluded that the available literature suggests potential reductions in withdrawal symptoms and cravings across opioids and other substances, while also emphasizing limitations of the evidence base and the need for better-controlled research.[4]
Naturalistic and observational studies have reported improvements in withdrawal and substance use outcomes in some cohorts, but these designs are vulnerable to selection bias, variable dosing and aftercare, and reliance on self-report, making causal conclusions uncertain compared with randomized trials.[2][3][4]
Beyond addiction, research and media reports have explored ibogaine’s possible relevance to conditions such as PTSD, depression, anxiety, and traumatic brain injury, but these are not established indications and remain investigational.[4][7][8]
Safety risks and contraindications
Ibogaine carries significant medical risk, with the most emphasized concern being cardiac toxicity: QTc prolongation can increase the risk of dangerous arrhythmias such as torsades de pointes, particularly in susceptible individuals or when combined with other substances and medications that also affect cardiac conduction.[2][5][6]
Medical summaries commonly warn that risk may be elevated by pre-existing heart conditions (including long QT syndrome), electrolyte abnormalities, polysubstance use, and drug–drug interactions, and they therefore recommend screening (e.g., ECG) and appropriate medical monitoring in any setting where ibogaine is administered.[5][6]
Neuropsychiatric adverse effects have also been reported in general descriptions, including anxiety, confusion, and potential triggering of mania in vulnerable individuals, which is one reason many programs list severe or unstable psychiatric illness among common exclusion criteria.[2][5]
Because opioid detoxification itself can involve dehydration and vomiting, harm-reduction discussions emphasize managing hydration and electrolytes and planning post-detox overdose prevention, since relapse after detox can occur with reduced opioid tolerance.[2][4][5]
Legal status and access
In the United States, ibogaine is classified as a Schedule I controlled substance, which restricts non-research use and limits availability within regulated medical systems.[6] Legal status varies widely by country, contributing to the existence of cross-border or international ibogaine clinics and differing levels of medical oversight.[5]
Some analyses note that clinics have operated in parts of North America (including cross-border settings) where local law and enforcement differ from U.S. federal scheduling, but the regulatory environment remains complex and subject to change.[5] Because legality does not guarantee medical quality, sources aimed at the public commonly emphasize verifying medical screening practices and emergency preparedness when evaluating a provider.[2][5]
For practical planning considerations, including pricing drivers and what services are commonly included, see Ibogaine Treatment Cost: A Comprehensive Guide.[5]
Research directions: neuroplasticity and ibogaine-inspired drugs
Some contemporary research interest in ibogaine is linked to hypotheses about neuroplasticity and long-lasting changes in brain circuits relevant to addiction and mood, though direct clinical causality in humans remains under investigation.[4][8]
Because ibogaine can pose significant cardiac risk (including QTc prolongation), research groups and companies have explored ibogaine-inspired analogs and derivatives intended to retain therapeutic benefits while reducing toxicity and improving tolerability.[3][8]
Public-facing academic communications (including university news coverage) have highlighted this broader “ibogaine-inspired” pipeline for addiction and depression research, reflecting a trend toward developing compounds that may be easier to standardize and test in conventional clinical trials than plant-derived or non-standardized ibogaine preparations.[8]